Abstract
in their native kidneys and in renal transplants [2, 3]. Preliminary data from the FONT trial (NCT00814255) suggest that some patients treated with oral galactose achieve a significant reduction in proteinuria in parallel with a decline in Palb during 24 weeks of therapy (unpublished observations). In light of these findings, novel biomarkers may be needed to identify patient subgroups who are likely to respond to galactose treatment and a longer period of therapy may be required to fully realize the benefit of therapy. Agents such as rituximab, with response rates of approximately 20 % in pilot studies of steroid-resistant nephrotic syndrome are still under active investigation. Since galactose is non-toxic and since other proven therapeutic options are limited, it may be premature to abandon investigation of galactose and other agents that may inhibit the activity of circulating permeability factors. Additional trials in larger samples of well-characterized patients are warranted and prolonged therapy may show that galactose will reduce proteinuria in at least some patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
